Sodium Hydroxide → N-{1-[4-(4-methoxy-2-trifluoromethyl-phenoxy)-benzylcarbamoyl]-cyclopropyl}malonic acid monoamide
반응식
C([O:3][C:4](=[O:35])[CH2:5][C:6]([NH:8][C:9]1([C:12](=[O:34])[NH:13][CH2:14][C:15]2[CH:20]=[CH:19][C:18]([O:21][C:22]3[CH:27]=[CH:26][C:25]([O:28][CH3:29])=[CH:24][C:23]=3[C:30]([F:33])([F:32])[F:31])=[CH:17][CH:16]=2)[CH2:11][CH2:10]1)=[O:7])C.[OH-].[Na+]>C1COCC1>[CH3:29][O:28][C:25]1[CH:26]=[CH:27][C:22]([O:21][C:18]2[CH:17]=[CH:16][C:15]([CH2:14][NH:13][C:12]([C:9]3([NH:8][C:6](=[O:7])[CH2:5][C:4]([OH:35])=[O:3])[CH2:11][CH2:10]3)=[O:34])=[CH:20][CH:19]=2)=[C:23]([C:30]([F:31])([F:33])[F:32])[CH:24]=1참가 물질
4
반응물 2
생성물 1
시약·촉매·용매 1
실험 절차
33 mg (0.067 mmol) of N-{1-[4-(4-methoxy-2-trifluoromethyl-phenoxy)-benzylcarbamoyl]-cyclopropyl}-malonic acid monoamide monoethylester (from 109a) was stirred for 1 h at RT together with 1 mL sodium hydroxide solution 1M in 20 mL THF. The reaction mixture was evaporated down and the residue was purified by chromatography (reversed phase).